Autolus Therapeutics plc

NasdaqGS:AUTL Stock Report

Market Cap: US$955.3m

Autolus Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Autolus Therapeutics has a total shareholder equity of $527.8M and total debt of $238.7M, which brings its debt-to-equity ratio to 45.2%. Its total assets and total liabilities are $853.6M and $325.8M respectively.

Key information

45.2%

Debt to equity ratio

US$238.66m

Debt

Interest coverage ration/a
CashUS$705.94m
EquityUS$527.84m
Total liabilitiesUS$325.78m
Total assetsUS$853.62m

Recent financial health updates

Recent updates

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Autolus Therapeutics: Major Inflection Point On The Horizon

Jul 31

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Autolus: Developing Better CAR-T In Refractory ALL

Jul 20

Financial Position Analysis

Short Term Liabilities: AUTL's short term assets ($758.6M) exceed its short term liabilities ($40.9M).

Long Term Liabilities: AUTL's short term assets ($758.6M) exceed its long term liabilities ($284.9M).


Debt to Equity History and Analysis

Debt Level: AUTL has more cash than its total debt.

Reducing Debt: AUTL's debt to equity ratio has increased from 0% to 45.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUTL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AUTL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.